OLD Mission Capital LLC maintained its position in shares of Galapagos NV (NASDAQ:GLPG) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,034 shares of the biotechnology company’s stock at the end of the second quarter. OLD Mission Capital LLC’s holdings in Galapagos NV were worth $3,192,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in Galapagos NV during the first quarter worth about $161,000. Acadian Asset Management LLC bought a new position in Galapagos NV during the second quarter worth about $166,000. New York State Common Retirement Fund bought a new position in Galapagos NV during the second quarter worth about $166,000. Pacad Investment Ltd. bought a new position in Galapagos NV during the second quarter worth about $168,000. Finally, Cim Investment Mangement Inc. bought a new position in Galapagos NV during the first quarter worth about $203,000. Institutional investors and hedge funds own 23.62% of the company’s stock.
GLPG has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $98.00 target price on shares of Galapagos NV in a report on Tuesday, June 20th. Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a report on Wednesday, June 21st. Nomura reduced their target price on Galapagos NV from $108.00 to $121.00 and set a “buy” rating on the stock in a report on Thursday, June 22nd. Instinet reiterated a “buy” rating and set a $108.00 target price (down from $121.00) on shares of Galapagos NV in a report on Thursday, June 22nd. Finally, Janney Montgomery Scott upgraded Galapagos NV from a “sell” rating to a “neutral” rating in a report on Friday, July 7th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $108.14.
Galapagos NV (NASDAQ GLPG) traded down 0.35% during mid-day trading on Wednesday, hitting $103.66. The company’s stock had a trading volume of 38,135 shares. The firm’s market cap is $5.27 billion. Galapagos NV has a 52-week low of $57.16 and a 52-week high of $104.06. The firm has a 50 day moving average of $101.43 and a 200-day moving average of $101.43.
Galapagos NV Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.